Australia Medical Cannabis Market By Source (Hemp and Marijuana), By Derivative (CBD, THC and Others), By Application (Chronic Pain, Cancer, Anxiety and Depression, Arthritis, Epilepsy and Others), Region and Companies – Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2026-2035

Published date: March 2026
Report ID: 180283
Number of Pages: 288
Format:

Table of Content
- 1. Research Methodology and Data Source
  - 1.1. Methodology/Research Approach
  - 1.2. Market Size Estimation
  - 1.3. Market Breakdown and Data Triangulation
  - 1.4. Data Sources
  - 1.5. Secondary Sources
  - 1.6. Primary Sources
- 2. Executive Summary
  - 2.1. Taxonomy
  - 2.2. Market Outlook
  - 2.3. Key Facts and Figures
  - 2.4. Major Players in Australia Medical Cannabis Market
- 3. Market Overview
  - 3.1. Industry Overview
  - 3.2. Segmental Overview
  - 3.3. Market Dynamics
    
    3.3.1. Drivers
    
    3.3.2. Restraints
    
    3.3.3. Opportunities
    
    3.3.4. Trends
  - 3.4. Regulatory Framework
  - 3.5. Opportunity Map Analysis
  - 3.6. Opportunity Orbits
  - 3.7. Market Investment Feasibility Index
  - 3.8. PESTLE Analysis
  - 3.9. PORTER’S Five Force Analysis
  - 3.10. Drivers & Restraints Impact Analysis
  - 3.11. Patient Journey Mapping
  - 3.12. Technological Landscape
  - 3.13. Product Life Cycle Analysis
  - 3.14. Value Chain Analysis
    
    3.14.1. List of Raw Material Suppliers
    
    3.14.2. List of Australia Medical Cannabis Manufacturers
    
    3.14.3. List of Dealer/Distributors
    
    3.14.4. List of Potential Customers
  - 3.15. Cost Structure Analysis
- 4. Macro-economic Factors
- 5. Impact of Current Geopolitical Scenario
- 6. Australia Medical Cannabis Market Analysis and Forecast, By Source
  - 6.1. Key Findings
  - 6.2. Australia Medical Cannabis Market Size Value (US$ Mn) Forecast, By Source, 2020-2035
    
    6.2.1. Hemp
    
    6.2.2. Marijuana
  - 6.3. Australia Medical Cannabis Market Attractiveness Analysis, By Source
- 7. Australia Medical Cannabis Market Analysis and Forecast, By Derivative
  - 7.1. Key Findings
  - 7.2. Australia Medical Cannabis Market Size Value (US$ Mn) Forecast, By Derivative, 2020-2035
    
    7.2.1. CBD
    
    7.2.2. THC
    
    7.2.3. Others
  - 7.3. Australia Medical Cannabis Market Attractiveness Analysis, By Derivative
- 8. Australia Medical Cannabis Market Analysis and Forecast, By Application
  - 8.1. Key Findings
  - 8.2. Australia Medical Cannabis Market Size Value (US$ Mn) Forecast, By Application, 2020-2035
    
    8.2.1. Chronic Pain
    
    8.2.2. Cancer
    
    8.2.3. Anxiety and Depression
    
    8.2.4. Arthritis
    
    8.2.5. Epilepsy
    
    8.2.6. Others
  - 8.3. Australia Medical Cannabis Market Attractiveness Analysis, By Application
- 9. Competitive Landscape & Company Profiles
  - 9.1. Market Competition Scenario Analysis, By Company
  - 9.2. Competitor Landscape
  - 9.3. Company Share Analysis
  - 9.4. Company Profiles
    
    9.4.1. Cann Group
    
    9.4.1.1. Company Details
    
    9.4.1.2. Business Overview
    
    9.4.1.3. Product Portfolio
    
    9.4.1.4. Financial Insights
    
    9.4.1.5. Key Developments (Investment & Expansion, Merger & Acquisition, Partnership & Agreement and New Product Development)
    
    9.4.1.6. SWOT Analysis
    
    9.4.1.7. Geographic Footprint
    
    9.4.2. Zelira
    
    9.4.2.1. Company Details
    
    9.4.2.2. Business Overview
    
    9.4.2.3. Product Portfolio
    
    9.4.2.4. Financial Insights
    
    9.4.2.5. Key Developments (Investment & Expansion, Merger & Acquisition, Partnership & Agreement and New Product Development)
    
    9.4.2.6. SWOT Analysis
    
    9.4.2.7. Geographic Footprint
    
    9.4.3. AusCann
    
    9.4.3.1. Company Details
    
    9.4.3.2. Business Overview
    
    9.4.3.3. Product Portfolio
    
    9.4.3.4. Financial Insights
    
    9.4.3.5. Key Developments (Investment & Expansion, Merger & Acquisition, Partnership & Agreement and New Product Development)
    
    9.4.3.6. SWOT Analysis
    
    9.4.3.7. Geographic Footprint
    
    9.4.4. Bod Science
    
    9.4.4.1. Company Details
    
    9.4.4.2. Business Overview
    
    9.4.4.3. Product Portfolio
    
    9.4.4.4. Financial Insights
    
    9.4.4.5. Key Developments (Investment & Expansion, Merger & Acquisition, Partnership & Agreement and New Product Development)
    
    9.4.4.6. SWOT Analysis
    
    9.4.4.7. Geographic Footprint
    
    9.4.5. Althea
    
    9.4.5.1. Company Details
    
    9.4.5.2. Business Overview
    
    9.4.5.3. Product Portfolio
    
    9.4.5.4. Financial Insights
    
    9.4.5.5. Key Developments (Investment & Expansion, Merger & Acquisition, Partnership & Agreement and New Product Development)
    
    9.4.5.6. SWOT Analysis
    
    9.4.5.7. Geographic Footprint
    
    9.4.6. Little Green Pharma
    
    9.4.6.1. Company Details
    
    9.4.6.2. Business Overview
    
    9.4.6.3. Product Portfolio
    
    9.4.6.4. Financial Insights
    
    9.4.6.5. Key Developments (Investment & Expansion, Merger & Acquisition, Partnership & Agreement and New Product Development)
    
    9.4.6.6. SWOT Analysis
    
    9.4.6.7. Geographic Footprint
    
    9.4.7. Incannex
    
    9.4.7.1. Company Details
    
    9.4.7.2. Business Overview
    
    9.4.7.3. Product Portfolio
    
    9.4.7.4. Financial Insights
    
    9.4.7.5. Key Developments (Investment & Expansion, Merger & Acquisition, Partnership & Agreement and New Product Development)
    
    9.4.7.6. SWOT Analysis
    
    9.4.7.7. Geographic Footprint
    
    9.4.8. Vitura Health
    
    9.4.8.1. Company Details
    
    9.4.8.2. Business Overview
    
    9.4.8.3. Product Portfolio
    
    9.4.8.4. Financial Insights
    
    9.4.8.5. Key Developments (Investment & Expansion, Merger & Acquisition, Partnership & Agreement and New Product Development)
    
    9.4.8.6. SWOT Analysis
    
    9.4.8.7. Geographic Footprint
    
    9.4.9. Bioxyne
    
    9.4.9.1. Company Details
    
    9.4.9.2. Business Overview
    
    9.4.9.3. Product Portfolio
    
    9.4.9.4. Financial Insights
    
    9.4.9.5. Key Developments (Investment & Expansion, Merger & Acquisition, Partnership & Agreement and New Product Development)
    
    9.4.9.6. SWOT Analysis
    
    9.4.9.7. Geographic Footprint
    
    9.4.10. Green Farmers
    
    9.4.10.1. Company Details
    
    9.4.10.2. Business Overview
    
    9.4.10.3. Product Portfolio
    
    9.4.10.4. Financial Insights
    
    9.4.10.5. Key Developments (Investment & Expansion, Merger & Acquisition, Partnership & Agreement and New Product Development)
    
    9.4.10.6. SWOT Analysis
    
    9.4.10.7. Geographic Footprint
    
    9.4.11. ECS Botanics
    
    9.4.11.1. Company Details
    
    9.4.11.2. Business Overview
    
    9.4.11.3. Product Portfolio
    
    9.4.11.4. Financial Insights
    
    9.4.11.5. Key Developments (Investment & Expansion, Merger & Acquisition, Partnership & Agreement and New Product Development)
    
    9.4.11.6. SWOT Analysis
    
    9.4.11.7. Geographic Footprint
    
    9.4.12. Tasmanian Botanics
    
    9.4.12.1. Company Details
    
    9.4.12.2. Business Overview
    
    9.4.12.3. Product Portfolio
    
    9.4.12.4. Financial Insights
    
    9.4.12.5. Key Developments (Investment & Expansion, Merger & Acquisition, Partnership & Agreement and New Product Development)
    
    9.4.12.6. SWOT Analysis
    
    9.4.12.7. Geographic Footprint
List of Tables
- Table 1: Australia Medical Cannabis Market Value (US$ Mn), By Source, 2020-2035
- Table 2: Australia Medical Cannabis Market Value (US$ Mn), By Derivative, 2020-2035
- Table 3: Australia Medical Cannabis Market Value (US$ Mn), By Application, 2020-2035
List of Figures
- Figure 1: Australia Medical Cannabis Market Value (US$ Mn), 2020-2035
- Figure 2: Australia Medical Cannabis Market Value Share (%) Analysis, By Source, 2025 & 2035
- Figure 3: Australia Medical Cannabis Market Value Share (%) Analysis, By Derivative, 2025 & 2035
- Figure 4: Australia Medical Cannabis Market Value Share (%) Analysis, By Application, 2025 & 2035
- Cann Group (Refinanced and debt-restructured in 2025)
- Zelira Therapeutics
- AusCann Group Holdings Ltd
- Bod Science
- Althea Group
- Little Green Pharma (Announced merger with Cannatrek in Jan 2026)
- Incannex Healthcare
- Vitura Health Limited (Formerly Cronos Australia)
- Bioxyne
- Green Farmers
- ECS Botanics
- Tasmanian Botanics